Top-News
Pharmazeutika USA

Inovio Pharmaceuticals News

Aktie
WKN:  A400EJ ISIN:  US45773H4092 US-Symbol:  INO
10,84 €
-0,30 €
-2,69%
06.05.24 19:02:37
Handeln Depot/Watchlist
Aktienanzahl *
1,82 Mio.
Marktkapitalisierung *
20,51 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 25.01.2024

Inovio Pharmaceuticals News

01.05.24 - PR Newswire
INOVIO Reports Inducement Grants Under Inducement Plan
INOVIO Reports Inducement Grants Under Inducement Plan PR Newswire
29.04.24 - PR Newswire
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024 PR Newswire
29.04.24 - PR Newswire
INOVIO to Participate in Upcoming Investor Conferences in May
INOVIO to Participate in Upcoming Investor Conferences in May PR Newswire
15.04.24 - PR Newswire
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-​Funded Warrants PR Newswire
26.03.24 - PR Newswire
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine PR Newswire
06.03.24 - PR Newswire
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights PR Newswire
06.03.24 - PR Newswire
Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting PR Newswire
21.02.24 - PR Newswire
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024 PR Newswire
07.02.24 - PR Newswire
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire
02.02.24 - PR Newswire
INOVIO Reports Inducement Grant Under Inducement Plan
INOVIO Reports Inducement Grant Under Inducement Plan PR Newswire
23.01.24 - PR Newswire
INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split
INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split PR Newswire
22.01.24 - PR Newswire
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader PR Newswire
04.01.24 - PR Newswire
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-​tpzi) PR Newswire
03.01.24 - PR Newswire
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program PR Newswire
09.11.23 - PR Newswire
INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights
INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights PR Newswire
01.11.23 - PR Newswire
INOVIO Reports Inducement Grants Under Inducement Plan
INOVIO Reports Inducement Grants Under Inducement Plan PR Newswire
26.10.23 - PR Newswire
INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023
INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023 PR Newswire
10.10.23 - PR Newswire
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program PR Newswire
27.09.23 - PR Newswire
Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million
Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million PR Newswire
07.09.23 - PR Newswire
INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis PR Newswire

Newssuche

Videos

newspaper
06.05.24 +6,89%
Technical Trading: Rohöl Short Chance
Rohöl Short Typ: Turbo Open End WKN: VD4JF9 Hebel: 13 Laufzeit: OpenEnd Einstieg: Market ... Mehr »